SI-BONE (NASDAQ:SIBN) issued its quarterly earnings data on Sunday. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative return on equity of 45.03% and a negative net margin of 61.67%.
NASDAQ:SIBN traded down $2.96 during trading hours on Tuesday, reaching $33.00. 523,542 shares of the stock were exchanged, compared to its average volume of 290,663. The company has a quick ratio of 12.22, a current ratio of 12.65 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average of $33.10 and a two-hundred day moving average of $28.78. SI-BONE has a twelve month low of $14.37 and a twelve month high of $37.21. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -20.62 and a beta of 1.41.
In other news, CFO Laura Francis sold 18,358 shares of the stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $33.34, for a total value of $612,055.72. Following the sale, the chief financial officer now directly owns 197,471 shares in the company, valued at $6,583,683.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey W. Dunn sold 2,112 shares of the stock in a transaction on Friday, April 16th. The shares were sold at an average price of $33.65, for a total value of $71,068.80. The disclosure for this sale can be found here. Insiders have sold 1,067,472 shares of company stock worth $32,658,438 over the last 90 days. 15.50% of the stock is owned by insiders.
Several research analysts recently weighed in on the company. Truist Securities increased their price objective on SI-BONE from $35.00 to $43.00 in a research report on Tuesday. Canaccord Genuity increased their price objective on SI-BONE from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist increased their price objective on SI-BONE from $35.00 to $43.00 in a research report on Tuesday. Needham & Company LLC increased their price objective on SI-BONE from $34.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research lowered SI-BONE from a “hold” rating to a “sell” rating in a research report on Friday, March 12th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. SI-BONE currently has an average rating of “Buy” and an average price target of $36.63.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Further Reading: What is Depreciation?
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.